13.35% -0.9675

Clene Inc (CLNN)

Clene Inc 주식(CLNN)의 최신 뉴스

Clene Inc (CLNN)

Clene Inc 주식(CLNN)의 최신 뉴스

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data - StockTitan

Clene (NASDAQ:CLNN) Stock Quotes, Forecast and News Summary - Benzinga

Clene (NASDAQ:CLNN) Raised to “Strong-Buy” at EF Hutton Acquisition Co. I - Defense World

Clene Showcases Latest Advancements in Neurodegenerative Disease Treatment at H.C. Wainwright Conference - Vancity Buzz

Clene Inc (CLNN-Q) QuotePress Release - The Globe and Mail

EF Hutton sets price target on Clene shares with buy rating - Investing.com

Clene’s CNM-Au8 Aims to Revolutionize Treatment for Neurodegenerative Disorders - Vancity Buzz

The Globe and Mail - The Globe and Mail

Wall Street Analysts Think Clene (CLNN) Could Surge 873.45%: Read This Before Placing a Bet - Yahoo Finance UK

Clene to Present at H.C. Wainwright Global Investment Conference, Highlighting Advances in Neurodegenerative Disease Treatment - Vancity Buzz

IBN Coverage: Clene (NASDAQ: CLNN) Management to Present at H.C. Wainwright Investment Conference - Yahoo Finance

Clene Advances Innovative Treatment for Neurodegenerative Diseases - Vancity Buzz

IBN Coverage: Clene (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases - Yahoo Finance

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference - ForexTV.com

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire Inc.

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases - MSN

Wall Street Analysts Think Clene (CLNN) Could Surge 873.45%: Read This Before Placing a Bet - MSN

IBN Coverage: Clene (NASDAQ: CLNN) CEO Discusses CNM-Au8(R) Trial Results on BioMedWire Podcast - Yahoo Finance

Clene’s CNM-Au8 Shows Promise in ALS and MS Treatment, CEO Discusses Trial Results - Vancity Buzz

IBN Coverage: Clene's (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers, Long-term Survival in ALS Trials - Yahoo Finance

How the (CLNN) price action is used to our Advantage - Stock Traders Daily

Oppenheimer analysts downgrades a Perform rating for Clene Inc (CLNN) - Knox Daily

IBN Coverage: Clene (NASDAQ: CLNN) Makes Strides in Developing CNM-Au8(R) to Address Neurodegenerative Conditions - Yahoo Finance

Wall Street Analysts Believe Clene (CLNN) Could Rally 976.32%: Here's is How to Trade - Yahoo Finance UK

IBN Coverage: Clene (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast Episode - Yahoo Finance

HC Wainwright Boosts Clene (NASDAQ:CLNN) Price Target to $31.00 - Defense World

HC Wainwright Brokers Increase Earnings Estimates for Clene Inc. (NASDAQ:CLNN) - Defense World

Clene submits new CNM-Au8 data to FDA ahead of upcoming meeting - ALS News Today

IBN Coverage: Clene (NASDAQ: CLNN) Releases Q2 2024 Financial Results, Provides Updates - Yahoo Finance

IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc. - GlobeNewswire

IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc. - Yahoo Finance

A Guide To The Risks Of Investing In Clene Inc (CLNN) - Knox Daily

Clene Inc. (CLNN) Reports Q2 Loss, Lags Revenue Estimates - MSN

Clene shares target boosted by H.C. Wainwright, 'clinical efficacy in ALS' noted - Investing.com Canada

Clene shares target boosted by H.C. Wainwright, 'clinical efficacy in ALS' noted - Investing.com

Clene Inc Inc. (CLNN) Price Performance: A Guide to Technical Indicators - The InvestChronicle

Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights - wallstreet:online

Clene shares target boosted by H.C. Wainwright, 'clinical efficacy in ALS' noted - Investing.com UK

Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights - StockTitan

Clene’s (CLNN) “Buy” Rating Reiterated at Canaccord Genuity Group - Defense World

Clene Announces New CNM-Au8® Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS - StockTitan

Clene (NASDAQ: CLNN) Announces Participation In Canaccord Genuity 44th Annual Growth Conference - Barchart

Clene stock hits 52-week low at $4.19 amid sharp annual decline - Investing.com

Clene to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company ... - Enid News & Eagle

Clene Inc. (NASDAQ:CLNN) Short Interest Update - Defense World

Clene Inc. regains compliance with Nasdaq listing standards By Investing.com - Investing.com Australia

Clene Inc. regains compliance with Nasdaq listing standards - Investing.com India

Clene Inc. regains compliance with Nasdaq listing standards - Investing.com

Clene Inc. regains compliance with Nasdaq listing standards By Investing.com - Investing.com South Africa

Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire Inc.

Clene to submit new CNM-Au8 data to FDA ahead of meeting - ALS News Today

CLNN과 유사한 종목